Plant ID: NPO22562
Plant Latin Name: Atractylodes macrocephala koidz
Taxonomy Genus: Atractylodes
Taxonomy Family: Asteraceae
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
n.a.
GRM8; GRM1; | |
ADORA3; | |
BLM; CDA; | |
GRIA4; GRIA2; GRIK3; GRIK5; GRIK1; | |
CA9; | |
NFKB1; | |
SLC1A1; | |
FABP4; LMNA; |
Cytochrome P450 Enzymes: | CYP3A4; |
---|
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
Enzyme_unclassified | CDA | Cytidine deaminase | P32320 | CHEMBL4502 |
Ionotropic glutamate receptor | GRIA4 | Glutamate receptor ionotropic, AMPA 4 | P48058 | CHEMBL3190 |
Ionotropic glutamate receptor | GRIA2 | Glutamate receptor ionotropic, AMPA 2 | P42262 | CHEMBL4016 |
Ionotropic glutamate receptor | GRIK3 | Glutamate receptor ionotropic kainate 3 | Q13003 | CHEMBL3684 |
Ionotropic glutamate receptor | GRIK5 | Glutamate receptor ionotropic kainate 5 | Q16478 | CHEMBL2675 |
Ionotropic glutamate receptor | GRIK1 | Glutamate receptor ionotropic kainate 1 | P39086 | CHEMBL1918 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
SLC superfamily of solute carriers | SLC1A1 | Excitatory amino acid transporter 3 | P43005 | CHEMBL2721 |
Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
Small molecule receptor (family C GPCR) | GRM8 | Metabotropic glutamate receptor 8 | O00222 | CHEMBL3228 |
Small molecule receptor (family C GPCR) | GRM1 | Metabotropic glutamate receptor 1 | Q13255 | CHEMBL3772 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0005215; transporter activity | GO:0005234; extracellularly glutamate-gated ion channel activity | 2.253E-12 | 1.226E-08 | GRIA2, GRIA4, GRIK1, GRIK3, GRIK5 |
BP | GO:0009987; cellular process | GO:0035235; ionotropic glutamate receptor signaling pathway | 1.270E-11 | 5.532E-08 | GRIA2, GRIA4, GRIK1, GRIK3, GRIK5 |
BP | GO:0023052; signaling | GO:0060079; excitatory postsynaptic potential | 2.126E-09 | 3.858E-06 | GRIA2, GRIA4, GRIK1, GRIK3, GRIK5 |
MF | GO:0005215; transporter activity | GO:0015277; kainate selective glutamate receptor activity | 4.658E-09 | 6.762E-06 | GRIK1, GRIK3, GRIK5 |
BP | GO:0009987; cellular process | GO:0007196; adenylate cyclase-inhibiting G-protein coupled glutamate receptor signaling pathway | 3.905E-08 | 5.002E-05 | GRIK3, GRM1, GRM8 |
BP | GO:0023052; signaling | GO:0051966; regulation of synaptic transmission, glutamatergic | 1.390E-07 | 1.513E-04 | GRIK1, GRIK3, GRM1, GRM8 |
CC | GO:0044456; synapse part | GO:0045211; postsynaptic membrane | 5.875E-07 | 5.815E-04 | GRIA2, GRIA4, GRIK1, GRIK3, GRIK5 |
MF | GO:0005215; transporter activity | GO:0004971; AMPA glutamate receptor activity | 3.856E-06 | 2.399E-03 | GRIA2, GRIA4 |
MF | GO:0005215; transporter activity | GO:0008381; mechanosensitive ion channel activity | 5.522E-06 | 3.006E-03 | GRIA2, GRIA4, GRIK1, GRIK3, GRIK5 |
CC | GO:0044425; membrane part | GO:0008328; ionotropic glutamate receptor complex | 6.926E-06 | 3.588E-03 | GRIA2, GRIA4, GRIK5 |
MF | Unclassified; | GO:0004872; receptor activity | 1.239E-05 | 5.506E-03 | ADORA3, GRIA2, GRIA4, GRIK1, GRIK3, GRIK5, GRM1, GRM8 |
CC | GO:0044456; synapse part | GO:0042734; presynaptic membrane | 1.712E-05 | 7.168E-03 | GRIK5, GRM1, GRM8 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09150 Organismal Systems | 09156 Nervous system | hsa04724 | Glutamatergic synapse | 1.076E-14 | 9.466E-13 | GRIA2, GRIK5, SLC1A1, GRM8, GRIK3, GRIK1, GRM1, GRIA4 |
09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 1.431E-11 | 6.297E-10 | GRIA2, GRIK5, ADORA3, GRM8, GRIK3, GRIK1, GRM1, GRIA4 |
09150 Organismal Systems | 09156 Nervous system | hsa04723 | Retrograde endocannabinoid signaling | 6.674E-05 | 1.958E-03 | GRIA2, GRM1, GRIA4 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 4.939E-04 | 8.678E-03 | GRIA2, NFKB1, GRIA4 |
09160 Human Diseases | 09164 Substance dependence | hsa05033 | Nicotine addiction | 4.598E-04 | 8.678E-03 | GRIA2, GRIA4 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00983 | Drug metabolism - other enzymes | 6.084E-04 | 8.678E-03 | CDA, CYP3A4 |
09160 Human Diseases | 09164 Substance dependence | hsa05030 | Cocaine addiction | 6.903E-04 | 8.678E-03 | GRIA2, NFKB1 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
C00-D49: Neoplasms | Cancer | C00-C96 | NFKB1; ADORA3; CA9; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | GRM1; |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | GRIK1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; |
NA: NA | Hepatitis C virus infection | NA | ADORA3; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | GRM1; GRIK1; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | GRIA2; GRIA4; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | GRM1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3; |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | GRM1; GRIK1; |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | GRM1; GRIK1; |
C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | GRM1; |
A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | GRIK1; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA3; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | CDA; CA9; |
C00-D49: Neoplasms | Breast cancer | C50 | CA9; |